Kuo Shu-Chen, Tan Mei-Chen, Huang Wei-Cheng, Wu Han-Chieh, Chen Feng-Jui, Liao Yu-Chieh, Wang Hui-Ying, Shiau Yih-Ru, Lauderdale Tsai-Ling
National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, Taiwan.
Institute of Population Health Sciences, National Health Research Institutes, Miaoli, Taiwan.
J Antimicrob Chemother. 2021 Feb 11;76(3):653-658. doi: 10.1093/jac/dkaa499.
We aimed to determine susceptibilities of Elizabethkingia spp. to 25 commonly tested and 8 novel antibiotics, and to compare the performance of different susceptibility testing methods.
Clinical isolates of Elizabethkingia spp., Chryseobacterium spp. and Flavobacterium spp. collected during 2002-18 (n = 210) in a nationwide surveillance programme in Taiwan were speciated by 16S rRNA sequencing. MICs were determined by broth microdilution. The broth microdilution results of 18 common antibiotics were compared with those obtained by the VITEK 2 automated system.
Among the Elizabethkingia spp. identified (n = 108), Elizabethkingia anophelis was the most prevalent (n = 90), followed by Elizabethkingia meningoseptica (n = 7) and Elizabethkingia miricola cluster [E. miricola (n = 6), Elizabethkingia bruuniana (n = 3) and Elizabethkingia ursingii (n = 2)]. Most isolates were recovered from respiratory or blood specimens from hospitalized, elderly patients. PFGE showed two major and several minor E. anophelis clones. All isolates were resistant to nearly all the tested β-lactams. Doxycycline, minocycline and trimethoprim/sulfamethoxazole inhibited >90% of Elizabethkingia spp. Rifampin inhibited E. meningoseptica (100%) and E. anophelis (81.1%). Fluoroquinolones and tigecycline were active against E. meningoseptica and E. miricola cluster isolates. Novel antibiotics, including imipenem/relebactam, meropenem/vaborbactam, ceftazidime/avibactam, cefepime/zidebactam, delafloxacin, eravacycline and omadacycline were ineffective but lascufloxacin inhibited half of Elizabethkingia spp. The very major discrepancy rates of VITEK 2 were >1.5% for ciprofloxacin, moxifloxacin and vancomycin. Major discrepancy rates were >3% for amikacin, tigecycline, piperacillin/tazobactam and trimethoprim/sulfamethoxazole.
MDR, absence of standard interpretation criteria and poor intermethod concordance necessitate working guidelines to facilitate future research of emerging Elizabethkingia spp.
我们旨在确定伊丽莎白菌属对25种常用测试抗生素和8种新型抗生素的敏感性,并比较不同药敏试验方法的性能。
在台湾一项全国性监测计划中,于2002年至2018年期间收集的伊丽莎白菌属、金黄杆菌属和黄杆菌属的临床分离株(n = 210),通过16S rRNA测序进行菌种鉴定。采用肉汤微量稀释法测定最低抑菌浓度(MIC)。将18种常用抗生素的肉汤微量稀释结果与VITEK 2自动系统获得的结果进行比较。
在鉴定出的伊丽莎白菌属(n = 108)中,嗜蚊伊丽莎白菌最为常见(n = 90),其次是脑膜败血伊丽莎白菌(n = 7)和米氏伊丽莎白菌群[米氏伊丽莎白菌(n = 6)、布鲁氏伊丽莎白菌(n = 3)和厄氏伊丽莎白菌(n = 2)]。大多数分离株来自住院老年患者的呼吸道或血液标本。脉冲场凝胶电泳(PFGE)显示嗜蚊伊丽莎白菌有两个主要克隆和几个次要克隆。所有分离株对几乎所有测试的β-内酰胺类抗生素均耐药。强力霉素、米诺环素和甲氧苄啶/磺胺甲恶唑对>90%的伊丽莎白菌属有抑制作用。利福平对脑膜败血伊丽莎白菌(100%)和嗜蚊伊丽莎白菌(81.1%)有抑制作用。氟喹诺酮类和替加环素对脑膜败血伊丽莎白菌和米氏伊丽莎白菌群分离株有活性。新型抗生素,包括亚胺培南/瑞来巴坦、美罗培南/瓦博巴坦、头孢他啶/阿维巴坦、头孢吡肟/齐地巴坦、德拉氟沙星、依拉环素和奥马环素均无效,但拉舒沙星对一半的伊丽莎白菌属有抑制作用。VITEK 2对环丙沙星、莫西沙星和万古霉素的非常主要误差率>1.5%。对阿米卡星、替加环素、哌拉西林/他唑巴坦和甲氧苄啶/磺胺甲恶唑的主要误差率>3%。
多重耐药、缺乏标准解释标准以及方法间一致性差,需要制定工作指南以促进对新兴伊丽莎白菌属的未来研究。